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Full length cDNAs encoding both slow-twitch/cardiac (SERCA2) and fast-twitch skeletal muscle (SERCAl) Ca*+-ATPases were expressed by tran- 
sient transfection of COS-1 cells. Studies of the Cazf-dependency of Ca2+-transport in microsomes isolated from these cells showed that both 
isoforms had an affinity for Ca** of about 0.2 pM. The Cazf-affinity of SERCA2 was lowered when phospholamban was co-expressed with it, 
demonstrating that the two proteins interact in this expression system. These studies support the view that phospholamban inhibition accounts 
for the low Ca2+-atlinity and low activity of SERCA2 in cardiac muscle sarcoplasmic reticulum. 
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1. INTRODUCTION 
Ca2 ’ -ATPases play a crucial role in muscle relaxa- 
tion through their ability to pump Ca2 ’ out of the sar- 
coplasm [1,2]. At least 3 different Ca’ + -ATPase genes 
are expressed in mammalian cells [3-71. One isoform, 
SERCAl , is expressed almost exclusively in fast-twitch 
skeletal muscle [4,5), while SERCA2, and to a minor 
extent, SERCA3, are expressed in cardiac and slow- 
twitch skeletal muscles [3,5,7]. Thus most of the 
Ca2 + -transport activity of cardiac muscle sarcoplasmic 
reticulum can be ascribed to the SERCA2 isoform. The 
CaZ + -pump in cardiac sarcoplasmic reticulum vesicles 
has a lower affinity for Ca2 ’ than does the Ca’ + -pump 
in fast-twitch skeletal muscle sarcoplasmic reticulum 
[8]. It is not clear whether the low affinity for Ca2’ of 
SERCA2 in cardiac sarcoplasmic reticulum can be ex- 
plained entirely by the presence of the inhibitory pro- 
tein, phospholamban 121, or whether it is due to amino 
acid sequence differences, since the amino acid se- 
quence identity is only 76% between the two isoforms 
141. 
In this communications we demonstrate that the two 
isoforms expressed in isolation of other sarcoplasmic 
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The cDNAs encoding the full length rabbit SERCA2 f3] and 
SERCAl [4] cloned into the mammalian expression vector pcDX [9] 
were utilized for transfection of COS-t cells. The same cDNA inserts 
ligated into the expression vectors pRK1-4 and p91023(B) [lo,1 l] were 
also utilized. The construct for expression of rabbit phospholamban 
cDNA in p91023(B) was reported previously [12]. In order to assure 
co-expression of rabbit SERCA2 and phospholamban in the same 
cell, cDNAs encoding both SERCAZ and phospholamban cDNA 
were incorporated into one plasmid vector under the regulation of 
separate promoters. The expression vector pSVL (Pharmacia) was 
cleaved at unique EcoRI and Sal1 sites and a fragment containing the 
multiple cloning site and the elements necessary for cDNA expression 
in mammalian celis, inciuding the SV40 origin of replication, was 
isolated. This fragment was blunt-ended and ligated with Safi linkers. 
After d&e&ion with Saii, the fragment was Iigated into the unique 
S&J site in the pcDX vector containing full length SERCA2 cDNA 
f3], upstream of the regulatory sequences cantrolling expression of 
the ATPase. The rabbit phosphol~b~ cDNA fra8ment, fitted with 
S&I linkers [12], was then ligated into the unique S&I site in the pSVL- 
derived multiple cloning sequence. The same construct containing 
SERCA2 cDNA in the correct orientation and phospbolamban cDNA 
in the reverse orientation was utilized as a control for analysis of the 
effect of phospholamban on ATPase function. The construct was 
amplified and purified by CsCl-gradient centrifugation. 
*Present uddrers J.F., Department of Biochemistry, Osaka Uuiversi- COS-1 cells were transfected by the DEAE-dextran method [13] 
ty Medical School, 4-3-57 Nakanoshima, Kita-ku, Asaka 530, Japan; using 15 pg of the construct per 10 cm dish. Cells were harvested after 
KM., Department of Molecular Biology, Psychiatric Institute of 48 or 72 h and the microsomal fraction was prepared and utilized for 
Tokyo, 2-l-8 ~mjkit~wa~ Setagaya-ku, Tokyo 156, Japan Ca*“-uptake measurement and for immunob~otting as described 
reticulum proteins show almost the same Ca’ ’ -affinity, 
indicating that other components, including phospho- 
lamban, must be involved in suppression of the 
Ca2+ -affinity of the Ca’ + -ATPase in cardiac muscle 
sarcoplasmic reticulum. We also demonstrate that co- 
expression of SERCA2 with phospholamban lowers the 
affinity of the pump for Ca*+ . 
2, MATERIALS AND METHODS 
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previously [ill. A monoclonal antibody Al, raised against dog 
phospholamban [14] and a polyclonal antibody C4, raised against a 
fusion protein containing the N&-terminal one-fifth of the rabbit 
SERCA2 [6] were utilized for immunostaining to demonstrate xpres- 
sion of phospholamban and the Ca”’ -ATPase, respectively. 
3. RESULTS AND DISCUSSION 
In a previous publication [ll] we described the ex- 
pression of the rabbit SERCAl protein and measure- 
ment of Ca2+ -uptake activity by microsomes isolated 
from cDNA-transfeeted COS-1 cells. In this study, we 
show that SERCAZ can also be expressed in a func- 
tional form. Fig. IA indicates the time course of 
Ca2 + -uptake by the microsomes from cells transfected 
with SERCAl and SERCA2 cDNAs. Cat + -transport 
rates were linear for at least 20 min. When the 
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Fig. 1. Ca2+ -uptake by microsomes transfected with fast- (SERCAI) 
and slow-twitch/cardiac (SERCA2) muscle Ca2+-ATPase cDNAs. 
(A) Time course of Ca*+-uptake at 2 FM free Ca’+ and; (B) 
Ca2 * -dependency of Ca’ + -transport at a fiied time of 15 min, in the 
presence of various concentrations of free Ca2+ by SERCAl (A ), 
SERCA2 (0) and control microsomes (CI ). The experiments described 
in A and B were carried out with different preparations with different 
levels of expression of the Ca2+-ATPase, accounting for the dif- 
Fig. 2. Immunoblotting of microsomal proteins. 25 pg of microsomal 
proteins were separated by sodium dodecyl sulfate-polyacrylamide g l 
electrophoresis in 8% (A) and 12.5% (B) gels, and transferred to 
nitrocellulose membranes. Polyclonal antibody C4, (A) and 
monoclonal antibody Al, (B) were utilized to detect SERCA2 (110 
kDa) and phospholamban (27 kDa) expression, respectively. The 
microsomes are: lane 1, control; lane 2, transfected with vector only; 
lane 3, transfeeted with phospholamban cDNA; lane 4, transfected 
with SERCA2 cDNA; and lane 5, transfected with SERCA2 plus 
ferences in specific activities between the two experiments. phospho~amban cDNAs. 
Ca2 ’ -dependency of Ca2 + -transport was compared 
between the two isoforms by varying free 
Ca2+-concentrations in the assay media (Fig. IB), the 
Ca2 + -concentration required for half-maximal activity 
was found to be 0.1-0.2 pM in both cases. Since the 
Ca* + -affinity of the pump in cardiac sarcoplasmic 
reticulum has been reported to be 3-&fold lower than 
that in fast-twitch skeletal muscle sarcoplasmic 
reticulum 181, but the pumps have nearly the same 
Ca2 + -affinity in isolation, a component must exist in 
cardiac sarcoplasmic reticulum which alters the affinity 
of SERCA2 for Ca*+, thereby inhibiting its activity in 
low free Ca2 + -concentrations. Dephospho- 
phospholamban has been shown to be an inhibitor of 
SERCA2, but phosphorylation of phospholamban 
relieves this inhibitory effect [ 151, 
In order to investigate the effect of phospholamban 
on Ca2 ’ -uptake rates, we made an expression construct 
in which both SERCA2 and phospholamban cDNAs 
were ligated into one plasmic vector, but with separate 
promoters. As shown in Fig. 2, the cells transfected 
with the plasmic ~ont~ning these cDNAs expressed 
both proteins. Phospholamban synthesis was detected 
with the monoclonal antibody Al. Antibody C4 
detected not only the transfected Ca2 + -ATPase, ex- 
pressed as a result of transfection, but also the low level 
of endogenous Ca2 + -ATPase in COS-1 cell microsomes 
[6]. SERCA2 expressed together with phospholamban 
had a lower affinity for Ca2 + than SERCA2 expressed 
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Fig. 3. Cal+ -dependency of Cat + -transport by microsomes express- 
ing Ca* + -ATPase alone ( A ) and Ca2+ -ATPase plus phosphol~b~ 
(0). The relative Ca’ + -uptake rates measured at a fiied time of 15 min 
are shown, with the maximum Ca2+-uptake rates equal to 100%. 
Each data point represents the mean f the standard deviation for 
triplicate experiments with different microsomal preparations. 
alone (Fig. 3). The difference in affinity that could be 
attributed to co-expression with phospholamban was 
about 0.2-0.3 pCa units. This corresponds to the 
Ca* + -affinity in the native cardiac sarcoplasmic reti- 
culum preparation, where the difference in Ca2+ -af- 
finity attributable to phosphol~ban phosphorylation 
is about 0.3 pCa units [ 161. Thus it is clear not only that 
SERCA2 and SERCAl have the same intrinsic 
Ca* + -affinities but also that phospholamban alone is 
capable of altering the Ca*+-affinity of SERCA2. We 
also found that COS-1 cells cotransfected with 
SERCAl and phospholamban cDNAs displayed lower 
affinity for Ca2+ than that of SERCAl alone, similar 
to the results presented in Fig. 3 (not shown). 
Phospholamban seems to exert its effect on SERCA2 
through ionic interactions in the cytoplasmic domains 
of the two proteins [17,18]. Kim et al. [19] 
demonstrated an inhibitory interaction between 
SERCA2 and a peptide consisting of residues 1-25 of 
the cytoplasmic domain of phosphol~b~. They 
found that a high molar ratio between the synthetic 
phospholamban peptide and the Ca* + -ATPase protein 
was necessary to inhibit Ca* + -uptake activity in 
reconstituted vesicles, however. Since phospholamban 
forms a pentamer [20,21] and the intramembranous do- 
main is responsible for pentamer formation [12], the 
pentameric form may have a stronger interaction with 
the Ca* + -ATPase than the monomeric form. Although 
the stoichiometry is not clear, the most likely in vivo 
ratio is one phosphol~ban monomer per 
Ca* ’ -ATPase molecule 1221. 
It is possible that higher phospholamban expression 
might be necessary in our system to reproduce the same 
high inhibitory effect as that found in the native cardiac 
sarcoplasmic reticulum. No significant change in the 
Ca* + -dependency of Ca’ + -transport was observed, 
however, when an equimolar ratio of phospholamban 
cDNA in the p91023oj) vector [12] was transfected 
together with the modified pcDX expression vector con- 
taming both SERCA2 and phospholamban cDNAs. 
Under these conditions, the ratio between phospholam- 
ban and ATPase expression was increased, although 
total ATPase synthesis was decreased. An additional 
factor might be that the microenvironment of the en- 
doplasmic reticulum from COS-1 cells might differ 
from that of the sarcoplasmic reticulum, leading to 
changes in phospholamban function. For example, 
Suzuki and Wang [23] have shown that phosphatidy- 
linositol is important for maximal phosphorylation of 
phospholamban. 
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